ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE

  • Nahid rao Shri Guru Ram Rai University, Dehradun, Uttarakhand, India
  • Reenoo Jauhari Associate professor, Graphic Era University, Dehradun, Uttarakhand, India
  • Pallavi Godiyal Associate professor, Graphic Era University, Dehradun, Uttarakhand, India
  • Vaishali Sati Associate professor, Graphic Era University, Dehradun, Uttarakhand, India
  • Assem Babbar Assistant professor Shri Guru Ram Rai University, Dehradun, Uttarakhand, India
DOI https://doi.org/10.31069/japsr.v5i3.02

Abstract

Parkinson’s disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Although PD can develop at any age, it begins most commonly in older adults, with a peak age at the onset of around 60 years. Levodopa and dopamine agonists such as ropinirole are used in Parkinson’s treatment. This complete literature search was done using Google Scholar and PubMed. This review is to compare the safety and efficacy of ropinirole with that of Levodopa.

Keywords: Parkinson's disease, Ropinirole, Levodopa, Unified Parkinson's Disease Rating Scale (UPDRS), Dopamine agonist

Downloads

Download data is not yet available.
Statistics
911 Views | 1025 Downloads
How to Cite
rao, N., R. Jauhari, P. Godiyal, V. Sati, and A. Babbar. “ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE”. Journal of Applied Pharmaceutical Sciences and Research, Vol. 5, no. 3, Dec. 2022, pp. 17-27, doi:10.31069/japsr.v5i3.02.
Issue
Vol 5 No 3 (2022): Volume 5, Issue 3, 2022
Section
Review Articles

All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)

Under this license, you are free to:

  • Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt- remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes .
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.

Licensing policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.